CL2016003271A1 - Métodos para tratar infecciones - Google Patents

Métodos para tratar infecciones

Info

Publication number
CL2016003271A1
CL2016003271A1 CL2016003271A CL2016003271A CL2016003271A1 CL 2016003271 A1 CL2016003271 A1 CL 2016003271A1 CL 2016003271 A CL2016003271 A CL 2016003271A CL 2016003271 A CL2016003271 A CL 2016003271A CL 2016003271 A1 CL2016003271 A1 CL 2016003271A1
Authority
CL
Chile
Prior art keywords
methods
treat infections
approximately
treat
administration
Prior art date
Application number
CL2016003271A
Other languages
English (en)
Inventor
Danping Li
Scott J Hopkings
Jarrod Longcor
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016003271(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of CL2016003271A1 publication Critical patent/CL2016003271A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS PARA TRATAR, PREVENIR, O REDUCIR EL DE INFECCIONES MICROBIANAS AL MISMO TIEMPO QUE MINIMIZA LOS EFECTOS ADVERSOS GASTROINTESTINALES USANDO UN RÉGIMEN DE DOSIFICACIÓN DE DOS ETAPAS QUE COMPRENDE APROXIMADAMENTE 1 HASTA APROXIMADAMENTE 7 DÍAS DE ADMINISTRACIÓN INTRAVENOSA SEGUIDO POR APROXIMADAMENTE 1 HASTA APROXIMADAMENTE 14 DÍAS DE ADMINISTRACIÓN ORAL DE UN AGENTE ANTIMICROBIANO.</p>
CL2016003271A 2014-06-20 2016-12-20 Métodos para tratar infecciones CL2016003271A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014790P 2014-06-20 2014-06-20
US201462034468P 2014-08-07 2014-08-07

Publications (1)

Publication Number Publication Date
CL2016003271A1 true CL2016003271A1 (es) 2017-08-04

Family

ID=54868662

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003271A CL2016003271A1 (es) 2014-06-20 2016-12-20 Métodos para tratar infecciones

Country Status (17)

Country Link
US (2) US20150366858A1 (es)
EP (1) EP3157633A4 (es)
JP (1) JP2017518354A (es)
CN (1) CN106687179A (es)
AU (1) AU2015276911A1 (es)
BR (1) BR112016029896A2 (es)
CA (1) CA2952955A1 (es)
CL (1) CL2016003271A1 (es)
EA (1) EA201692531A1 (es)
EC (1) ECSP16095557A (es)
IL (1) IL249616A0 (es)
MX (1) MX2016017348A (es)
PH (1) PH12016502547A1 (es)
SV (1) SV2016005348A (es)
TW (1) TW201605447A (es)
UY (1) UY36183A (es)
WO (1) WO2015196076A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693695A (zh) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 一种德拉沙星葡甲胺盐的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
US7728143B2 (en) * 2004-10-08 2010-06-01 Abbott Laboratories Salt and crystalline forms thereof of a drug
WO2006110815A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
CN1943561A (zh) * 2006-08-23 2007-04-11 北京阜康仁生物制药科技有限公司 普卢利沙星口腔崩解片及其制备方法
US8497378B2 (en) * 2008-09-24 2013-07-30 Rib-X Pharmaceuticals, Inc. Process for making quinolone compounds
MX2011005117A (es) * 2008-11-15 2011-10-21 Rib X Pharmaceuticals Inc Composiciones antimicrobianas.
WO2010096551A2 (en) * 2009-02-18 2010-08-26 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
CA2904387C (en) * 2013-03-15 2021-12-07 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics

Also Published As

Publication number Publication date
TW201605447A (zh) 2016-02-16
IL249616A0 (en) 2017-02-28
UY36183A (es) 2016-01-29
AU2015276911A2 (en) 2018-04-26
JP2017518354A (ja) 2017-07-06
CN106687179A (zh) 2017-05-17
BR112016029896A2 (pt) 2017-08-22
AU2015276911A1 (en) 2017-01-12
EP3157633A4 (en) 2018-02-21
EP3157633A1 (en) 2017-04-26
US20170368055A1 (en) 2017-12-28
EA201692531A1 (ru) 2017-05-31
CA2952955A1 (en) 2015-12-23
SV2016005348A (es) 2017-03-02
US20150366858A1 (en) 2015-12-24
ECSP16095557A (es) 2017-03-31
WO2015196076A1 (en) 2015-12-23
PH12016502547A1 (en) 2017-04-10
MX2016017348A (es) 2017-04-06

Similar Documents

Publication Publication Date Title
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
TW201613887A (en) Antiproliferative compounds and methods of use thereof
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX2018006503A (es) Compuesto novedoso de bifenilo o una sal del mismo.
MX2019014041A (es) Inhibidores pirazolicos de magl.
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
MX2018010993A (es) Derivados de icariina e icaritina.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX2017016524A (es) Sistemas de administracion para liberacion controlada de farmacos.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
MX381776B (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
BR112017028468A2 (pt) formulação sólida oral, e método para preparar uma formulação sólida oral
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
CL2016003271A1 (es) Métodos para tratar infecciones
MX2019003697A (es) Sal de metformina de elafibranor que muestra una actividad doble para el tratamiento de la obesidad asociada a la esteatohepatitis no alcoholica (nash) y a la hipertrigliceridemia.